DCTH

Healthcare Medical Devices

Delcath Systems, Inc.

$15.13

-0.28 -1.82% today

Price History

Not enough data

Key Stats

Market Cap

524.99M

Avg Volume

482,346

P/E (TTM)

1513.00

EPS

$0.01

52W High

$17.42

52W Low

$8.12

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

336.22

P/B Ratio

4.33

P/S Ratio

5.50

EV/EBITDA

-296.60

EV/Revenue

4.52

PEG Ratio

1.60

Margins

Gross Margin 87.1%

Operating Margin 8.2%

Net Margin 0.6%

EBITDA Margin (1.5%)

Growth & Returns

Revenue Growth (YoY)

20.6%

Earnings Growth (YoY)

0.0%

Earnings Growth (QoQ)

(1.1%)

Return on Equity

0.5%

Return on Assets

(0.9%)

Liquidity & Leverage

Current Ratio

9.83

Quick Ratio

8.45

Debt / Equity

0.02

Total Cash

95.90M

Total Debt

2.46M

About

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.